Demonstration of Reverse Remodeling Effects of Entresto. Using Echocardiography Endocardial Surface Analysis
Summary
This study intends to measure the effects of valsartan/sacubitril compared to baseline standard medical heart failure therapy on reverse remodeling using echocardiographic endocardial surface analysis techniques to assess changes in ventricular volume, function, and shape.
Timeline
- Start
- 2016-04
- Primary completion
- 2019-04
- Completion
- 2019-04
Outcome
Mixed primary results
registry MEAN Open Label Entresto: Baseline: 32 (Standard Deviation 7) percentage of ejection fraction NCT02754518 ↗
registry MEAN Open Label Entresto: 1 year: 43 (Standard Deviation 9) percentage of ejection fraction NCT02754518 ↗
registry analysis (other test); Open Label Entresto; p <0.001; t-test, 2 sided NCT02754518 ↗
registry analysis (other test); Open Label Entresto; p = 0.13; t-test, 2 sided NCT02754518 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LCZ696 | Unknown | — | — |